



## Integra LifeSciences to Present at Three Conferences in March

PLAINSBORO, N.J., Feb. 23, 2007 (PRIME NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is scheduled to present at the Susquehanna International Group's SIGNificant Investment Options in Healthcare at The Omni Berkshire Place in New York on March 1, 2007, Raymond James 28th Annual Institutional Investors Conference at the Hyatt Regency Grand Cypress in Orlando, FL on March 5, 2007 and at the Cowen and Company 27th Annual Health Care Conference at The Boston Marriott Copley Place in Boston, MA on March 13, 2007.

The SIG presentation will be delivered by John Bostjancic, Vice President of Corporate Development and Investor Relations of Integra. The Raymond James presentation will be delivered by Maureen Bellantoni, Executive Vice President and Chief Financial Officer of Integra. The Cowen and Company presentation will be delivered by Gerard Carlozzi, Executive Vice President and Chief Operating Officer.

A live webcast of all three presentations will be available through a link provided on the home page of the Investor Relations section of Integra's website at <http://www.Integra-LS.com>. Additionally, a replay of the webcast will be available for two weeks following each presentation.

Each of the presentations will provide an overview of Integra's operations, with a focus on currently marketed products, sales distribution channels, and product pipeline, recent financial history, and Integra's overall business strategy for growth.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products are used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at <http://www.Integra-LS.com>.

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation  
John B. Henneman, III, Executive Vice President,  
Chief Administrative Officer  
(609) 936-2481  
[jhenneman@Integra-LS.com](mailto:jhenneman@Integra-LS.com)  
John Bostjancic, Vice President, Corporate Development  
and Investor Relations  
(609) 936-2239  
[jbostjancic@integra-LS.com](mailto:jbostjancic@integra-LS.com)